According to the research report, the global intravenous immunoglobulin market size is expected to touch USD 29.53 Billion by 2032, from USD 13.69 Billion in 2022, growing with a significant CAGR of 7.99% from 2023 to 2032.
The intravenous immunoglobulin report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global intravenous immunoglobulin in conjunction with the geographical landscape of this vertical have also been included in this report.
The report offers intricate dynamics about different aspects of the global intravenous immunoglobulin market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global intravenous immunoglobulin during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.precedenceresearch.com/sample/2996
This study covers a detailed segmentation of the global intravenous immunoglobulin market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global intravenous immunoglobulin market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.
Key Players
- Biotest AG
- Octapharma AG
- LFB Biotechnologies
- Grifols SA
- CSL Behring
- China Biologics Products Inc.
- Kedrion Biopharma
- BDI Pharma Inc.
Market Segmentation
By Product
- IGG
- IGA
- IGM
- IGE
- IGD
By Route of Administration
- Intravenous
- Subcutaneous
By Application
- Hypogammaglobulinemia
- Chronic Inflammatory demyelinating polyneuropathy (CIDP)
- Immunodeficiency diseases
- Myasthenia Gravis
- Multifocal motor neuropathy
- Idiopathic thrombocytopenic purpura (ITP)
- Inflammatory myopathies
- Specific antibody deficiency
- Guillain-Barre syndrome
By End-Users
- Hospitals
- Homecare
- Specialty Clinics
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Research Methodology
The research methodology adopted by analysts for compiling the global intravenous immunoglobulin report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global intravenous immunoglobulin market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Intravenous Immunoglobulin Market
5.1. COVID-19 Landscape: Intravenous Immunoglobulin Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Intravenous Immunoglobulin Market, By Product
8.1. Intravenous Immunoglobulin Market Revenue and Volume, by Product, 2023-2032
8.1.1. IGG
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. IGA
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
8.1.3. IGM
8.1.3.1. Market Revenue and Volume Forecast (2020-2032)
8.1.4. IGE
8.1.4.1. Market Revenue and Volume Forecast (2020-2032)
8.1.5. IGD
8.1.5.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Intravenous Immunoglobulin Market, By Route of Administration
9.1. Intravenous Immunoglobulin Market Revenue and Volume, by Route of Administration, 2023-2032
9.1.1. Intravenous
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Subcutaneous
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Intravenous Immunoglobulin Market, By Application
10.1. Intravenous Immunoglobulin Market Revenue and Volume, by Application, 2023-2032
10.1.1. Hypogammaglobulinemia
10.1.1.1. Market Revenue and Volume Forecast (2020-2032)
10.1.2. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
10.1.2.1. Market Revenue and Volume Forecast (2020-2032)
10.1.3. Immunodeficiency diseases
10.1.3.1. Market Revenue and Volume Forecast (2020-2032)
10.1.4. Myasthenia Gravis
10.1.4.1. Market Revenue and Volume Forecast (2020-2032)
10.1.5. Multifocal motor neuropathy
10.1.5.1. Market Revenue and Volume Forecast (2020-2032)
10.1.6. Idiopathic thrombocytopenic purpura (ITP)
10.1.6.1. Market Revenue and Volume Forecast (2020-2032)
10.1.7. Inflammatory myopathies
10.1.7.1. Market Revenue and Volume Forecast (2020-2032)
10.1.8. Specific antibody deficiency
10.1.8.1. Market Revenue and Volume Forecast (2020-2032)
10.1.9. Guillain-Barre syndrome
10.1.9.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 11. Global Intravenous Immunoglobulin Market, By End-Users
11.1. Intravenous Immunoglobulin Market Revenue and Volume, by End-Users, 2023-2032
11.1.1. Hospitals
11.1.1.1. Market Revenue and Volume Forecast (2020-2032)
11.1.2. Homecare
11.1.2.1. Market Revenue and Volume Forecast (2020-2032)
11.1.3. Specialty Clinics
11.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 12. Global Intravenous Immunoglobulin Market, By Distribution Channel
12.1. Intravenous Immunoglobulin Market Revenue and Volume, by Distribution Channel, 2023-2032
12.1.1. Hospital Pharmacy
12.1.1.1. Market Revenue and Volume Forecast (2020-2032)
12.1.2. Retail Pharmacy
12.1.2.1. Market Revenue and Volume Forecast (2020-2032)
12.1.3. Online Pharmacies
12.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 13. Global Intravenous Immunoglobulin Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.1.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.1.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.1.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.1.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.1.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.1.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.1.6.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.1.6.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.1.7.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.1.7.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.1.7.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.1.7.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2. Europe
13.2.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.2.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.2.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.2.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.2.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.2.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.2.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.2.7. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.2.8. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.2.9.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.2.9.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.2.10. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.2.11. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.12. France
13.2.12.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.2.12.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.2.12.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.2.12.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.2.13. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.2.14.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.2.14.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.2.14.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.2.15. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3. APAC
13.3.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.3.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.3.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.3.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.3.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.6. India
13.3.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.3.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.3.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.3.6.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.3.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.8. China
13.3.8.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.3.8.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.3.8.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.3.8.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.3.9. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.3.10.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.3.10.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.3.10.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.3.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.3.11.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.3.11.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.3.11.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.3.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4. MEA
13.4.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.4.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.4.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.4.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.4.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.4.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.4.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.4.6.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.4.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.4.8.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.4.8.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.4.8.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.4.9. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.4.10.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.4.10.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.4.10.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.4.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.4.11.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.4.11.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.4.11.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.4.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.5. Latin America
13.5.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.5.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.5.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.5.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.5.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.5.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.5.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.5.6.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.5.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.5.8.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.5.8.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.5.8.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.5.8.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
Chapter 14. Company Profiles
14.1. Biotest AG
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Octapharma AG
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. LFB Biotechnologies
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Grifols SA
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. CSL Behring
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. China Biologics Products Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Kedrion Biopharma
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. BDI Pharma Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments